

Korea's Lotte Biologics inks deal with US-based NJ Bio for antibody drug conjugates services

22 January 2024 | News

To provide end-to-end process development, clinical, and commercial bioconjugation services to ADC clients



South Korean firm Lotte Biologics has recently signed a strategic business agreement with NJ Bio (hereinafter referred to as NJ Bio, US-based Contract Research Organisation (CRO) specialising in development and clinical manufacturing of antibody drug conjugates (ADCs) and linker-payloads.

Bringing an ADC to market requires capabilities in manufacturing including ADC process development, analytical method development, method qualification and validation, linker-payload development and synthesis, stability studies, preclinical and phase 1-3 clinical manufacturing capabilities, clinical and commercial production of antibodies, and ADC manufacturing on a commercial scale.

NJ Bio will provide Lotte Biologics with technologies such as ADC process development, analytical method development, and linker-payload development and synthesis. Utilising these, Lotte Biologics will offer services such as preclinical studies, clinical and commercial product antibodies, and ADC manufacturing services to its clients.

Through this agreement, both NJ Bio and Lotte plan to bring great value to their clients by providing all these end-to-end manufacturing services for ADCs, including a site that Lotte has been expanding in the US to support ADC manufacture on a commercial scale.